loading page

TREATMENT FOR MULTIPLE MYELOMA IN HOSPITAL AT HOME: CLINICAL CHARACTERISTICS AND PATIENT CARE PATHWAYS
  • +3
  • Benedicte MITTAINE-MARZAC,
  • Matthieu DE STAMPA,
  • Odile MARQUESTAUT,
  • Alexandre GEORGES,
  • Joel ANKRI,
  • Philippe AEGERTER
Benedicte MITTAINE-MARZAC
Author Profile
Matthieu DE STAMPA
Assistance Publique - Hopitaux de Paris
Author Profile
Odile MARQUESTAUT
APHP
Author Profile
Alexandre GEORGES
Assistance Publique Hopitaux de Paris
Author Profile
Joel ANKRI
UVSQ
Author Profile
Philippe AEGERTER
UVSQ
Author Profile

Abstract

AIM To describe the clinical characteristics and the care pathways of patients with multiple myeloma (MM) benefiting from hospital at home (HAH) for their parenteral anticancer treatment METHOD A retrospective scheme conducted in HAH of Assistance-Publique des Hôpitaux de Paris (APHP). All patients starting bortezomib treatment line in HAH were included in 2015. Data collection was based on CHIMIO® software and on medical records. We analyzed the patient’s characteristics, their pathways, their long-term outcomes. RESULTS Of 536 patients treated for cancer in HAH, 154 patients received bortezomib. 73,4% patients began their first line for their symptomatic MM. Mean age was 70,6 years, 27,3 % under 65 years, 53,9% of men, 27,3% living alone, a median Karnofsky Performans Status of 70. One third of elderly lived alone, 16,1% required domestic help. The median number of courses was 6 (range: 1-14), the mean duration of treatment was 6,6 m (+ 3,5) in HAH. The median time to next treatment was 17,5 (range:0-50) months. After 24 months of follow-up after the first administration in HAH, 77,9% were alive. The median overall survival was still not reached at 4 years. 58,8% -mainly the youngest- went back to HAH for the subsequent treatment. CONCLUSION Patients treated in HAH for MM - regardless of age and therapeutic goal- were mainly independent, treated from the first line in a radius close to hospital. The involvement of HAH was achieved without safety issues nor compromised long-term outcomes. This study described the real-world patterns of patients benefiting from HAH.

Peer review status:UNDER REVIEW

02 Apr 2020Submitted to International Journal of Clinical Practice
06 Apr 2020Assigned to Editor
06 Apr 2020Submission Checks Completed
13 Apr 2020Review(s) Completed, Editorial Evaluation Pending
16 Apr 2020Reviewer(s) Assigned